Oncolytic Virus-Driven Biotherapies from Bench to Bedside
- PMID: 36879416
- DOI: 10.1002/smll.202206948
Oncolytic Virus-Driven Biotherapies from Bench to Bedside
Abstract
With advances in cancer biology and an ever-deepening understanding of molecular virology, oncolytic virus (OV)-driven therapies have developed rapidly and become a promising alternative to traditional cancer therapies. In recent years, satisfactory results for oncolytic virus therapy (OVT) are achieved at both the cellular and organismal levels, and efforts are being increasingly directed toward clinical trials. Unfortunately, OVT remains ineffective in these trials, especially when performed using only a single OV reagent. In contrast, integrated approaches, such as using immunotherapy, chemotherapy, or radiotherapy, alongside OVT have demonstrated considerable efficacy. The challenges of OVT in clinical efficacy include the restricted scope of intratumoral injections and poor targeting of intravenous administration. Further optimization of OVT delivery is needed before OVs become a viable therapy for tumor treatment. In this review, the development process and antitumor mechanisms of OVs are introduced. The advances in OVT delivery routes to provide perspectives and directions for the improvement of OVT delivery are highlighted. This review also discusses the advantages and limitations of OVT monotherapy and combination therapy through the lens of recent clinical trials and aims to chart a course toward safer and more effective OVT strategies.
Keywords: antitumor mechanisms; clinical trials; intravenous administration; oncolytic viruses; traditional cancer therapies.
© 2023 Wiley-VCH GmbH.
Similar articles
-
Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy.Nano Res. 2022;15(5):4137-4153. doi: 10.1007/s12274-021-4031-6. Epub 2022 Feb 14. Nano Res. 2022. PMID: 35194488 Free PMC article. Review.
-
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.J Transl Med. 2023 Jul 25;21(1):500. doi: 10.1186/s12967-023-04360-8. J Transl Med. 2023. PMID: 37491263 Free PMC article. Review.
-
Development of oncolytic virotherapy: from genetic modification to combination therapy.Front Med. 2020 Apr;14(2):160-184. doi: 10.1007/s11684-020-0750-4. Epub 2020 Mar 7. Front Med. 2020. PMID: 32146606 Free PMC article. Review.
-
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.Front Immunol. 2021 Oct 5;12:721830. doi: 10.3389/fimmu.2021.721830. eCollection 2021. Front Immunol. 2021. PMID: 34675919 Free PMC article. Review.
-
Improving systemic delivery of oncolytic virus by cellular carriers.Cancer Biol Med. 2025 Jan 17;21(12):1104-19. doi: 10.20892/j.issn.2095-3941.2024.0390. Cancer Biol Med. 2025. PMID: 39831754 Free PMC article. Review.
Cited by
-
Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective.Viruses. 2023 Jul 28;15(8):1645. doi: 10.3390/v15081645. Viruses. 2023. PMID: 37631987 Free PMC article. Review.
-
Tailoring an intravenously injectable oncolytic virus for augmenting radiotherapy.Cell Rep Med. 2025 May 20;6(5):102078. doi: 10.1016/j.xcrm.2025.102078. Epub 2025 Apr 14. Cell Rep Med. 2025. PMID: 40233744 Free PMC article.
-
Systemic Delivery Strategies for Oncolytic Viruses: Advancing Targeted and Efficient Tumor Therapy.Int J Mol Sci. 2025 Jul 18;26(14):6900. doi: 10.3390/ijms26146900. Int J Mol Sci. 2025. PMID: 40725148 Free PMC article. Review.
-
Immunotherapy for colorectal cancer.Front Immunol. 2024 Aug 21;15:1433315. doi: 10.3389/fimmu.2024.1433315. eCollection 2024. Front Immunol. 2024. PMID: 39238638 Free PMC article. Review.
-
Challenges and strategies toward oncolytic virotherapy for leptomeningeal metastasis.J Transl Med. 2024 Nov 5;22(1):1000. doi: 10.1186/s12967-024-05794-4. J Transl Med. 2024. PMID: 39501324 Free PMC article. Review.
References
-
- R. L. Siegel, K. D. Miller, H. E. Fuchs, A. Jemal, CA Cancer J. Clin. 2021, 71, 7.
-
- M. G. Lizio, R. Boitor, I. Notingher, Analyst 2021, 146, 3799.
-
- C. Y. Chen, Y. S. Lin, C. H. Chen, Y. J. Chen, J. Biomed. Sci. 2018, 25, 30.
-
- H. L. Kaufman, F. J. Kohlhapp, A. Zloza, Nat. Rev. Drug Discovery 2015, 14, 642.
-
- A. H. Choi, M. P. O'Leary, Y. Fong, N. G. Chen, Biomedicines 2016, 4, 18.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical